• Mastodynia in the context of breast diseases: complex approach for diagnostic and treatment in reproductive age women

Mastodynia in the context of breast diseases: complex approach for diagnostic and treatment in reproductive age women

HEALTH OF WOMAN. 2016.6(112):36–40; doi 10.15574/HW.2016.112.36 
 

Mastodynia in the context of breast diseases: complex approach for diagnostic and treatment in reproductive age women 
 

Syusyuka V., Neryanov K., Kyryakova P., Musin I., Bykov О.

Zaporozhye state medical University

Zaporizhia city multifield clinical hospital № 9

Diagnostic and treatment center «YULIS», Zaporozhye 
 

The objective: to evaluate effectiveness of complex treatment of dyshormonal breast diseases with mastodynia in reproductive age women.


Patients and methods. 82 women aged from 23 to 45 years with dyshormonal breast diseases (DBD) accompanied with mastodynia took part in the trial. Diagnosis has been verified based on the patients ‘complaints, clinical observation of mammary glands, instrumental, clinic and laboratory investigation methods (ultra sound examination, aspirational biopsy, bilateral mammography). Assessment of mastodynia severity conducted using visual analogue pain scale (VAPS) in points. Diagnostic of anxiety level among examined women carried out by using Spielberg – Hanin methodology. All patients got Vitokan (Fita®) 30 drops 3 times per day 20–30 min before meals in combination with local transdermal gel contained 1% of micronized progesterone – Progestogel® (Besins Healthcare). Treatment duration was 3 months. Patients’ examination conducted in 1–3–6 months.


Results. According to the Medical Center data, it was observed that diffuse dyshormonal breast diseases occupied leading positions among all breast pathologies reaching 45–47% share. All women included in the trial had complaints on cycle bilateral breast pain (mastodynia) which appeared 8–10–12 days before menses. Diffuse seals and tenderness have been discovered via palpation. Diffuse fibrocystic hyperplasia with dominated cystic component was found in 47.6% of women and was recognized as most frequent pathology based on the results of ultra-sound breast examination. Combined treatment of Progestogel® and Vitokan leads to reduction of mastodynia symptoms in 76.8% women after the 1st month of treatment/dynamic observation and in 95% of women after the next 3 months. It was shown statistically significant decrease in the level of situational anxiety after conducted treatment that led to improvement in mood. Conducted trial defined women’s subjective evaluation based on their complaints as the key factor of treatment effectiveness All objective methods of patient’s examination have secondary importance.


Conclusions. High effectiveness of Progestogel® and Vitokan combined therapy has positive impact on clinical presentation, psycho-emotional condition (decreased level of anxiety) and proved by objective and instrumental methods of examination with no side effects. This fact provides evidence for using proposed combination for treatment of dishormonal breast diseases.


Key words: dishormonal breast disease, mastodynia, treatment, herbal medicine, progesterone, Prozhestozhel, Vitokan.


REFERENCES

1. Aksel EM. 2006. Zlokachestvennyie novoobrazovaniya molochnoy zhelezyi: sostoyanie onkologicheskoy pomoschi, zabolevaemost i smertnost. Mammologiya 1:9–13.

2. Vybrani lektsii z klinichnoi onkolohii: navch. posibnyk. Za red. akad. NAMN Ukrainy prof. HV Bondaria i prof. SV Antipovoi. Luhansk, VAT «Luhanska oblasna drukarnia». 2009:560.

3. Efimenko OA. 2010. Rannyaya diagnostika i profilaktika disgormonalnyih zabolevaniy molochnoy zhelezyi – osnovyi preduprezhdeniya onkologicheskoy patologii. Zdorov’ya UkraYini 1:82–83.

4. Klinicheskaya mammologiya. Sovremennoe sostoyanie problemyi. Pod red. EB Kampovoy-Polevoy, SS Chistyakova. M, GEOTAR-Media. 2006:512.

5. Kogan IYu, Musina EV. 2009. Gestagennyie kontratseptivyi i mastopatiya. Zhurnal akusherstva i zhenskih bolezney LVIII;6:70–75.

6. Kogan IYu. 2010. Mastopatiya: novyie podhodyi k diagnostike i patogeneticheskoy terapii. Zhurnal akusherstva i zhenskih bolezney LIX;1:66–70.

7. Kotenko K. 2012. Rak molochnoy zhelezyi: budet li sovremennoe lechenie dostupno v Ukraine? Zdorove Ukrainyi. Onkologiya 1(20):31.

8. Litvinenko AA. 2013. Rak grudnoy zhelezyi: lechenie, reabilitatsiya i pervyie shagi v prognozirovanii riskov. Zdorove zhenschinyi 8(84):173–177.

9. Neyshtadt EL, Vorobeva OA. 2003. Patologiya molochnoy zhelezyi. SPb, Foliant:208.

10. Ovsyannikova TV. 2008. Disgormonalnaya patologiya molochnyih zhelez – vzglyad ginekologa. Dobrokachestvennyie zabolevaniya molochnyih zhelez. Klinicheskie lektsii. M:22–38.

11. Bilynskyi BT, Volodko NA, Hnatyshak AI, Halai OO ta in. 2004. Onkolohiia: pidruchnyk. Za red. prof. BT Bilynskoho. K, Zdorov’ia:528.

12. Veropotvelyan PN, Veropotvelyan NP, Sidak AE i dr. 2010. Razvitie molochnyih zhelez i lechenie fibrozno-kistoznoy mastopatii u yunyih i molodyih zhenschin. ZhInochiy lIkar 4:46–50.

13. Raygorodskiy DYa. 2002. Prakticheskaya psihodiagnostika. Metodiki i testyi. uch. posobie. (Red.-sost.). Samara, BAHRAH-M:672.

14. Roschina GF. 2010. Molochnaya zheleza: vozrastnyie osobennosti, zabolevaniya i taktika lecheniya. Meditsinskie aspektyi zdorovya zhenschinyi. Sbornik rekomendatsiy:162–182.

15. Tatarchuk TF, Efimenko OA. 2009. Gormonalnyie i negormonalnyie aspektyi disgormonalnyih zabolevaniy molochnyih zhelez. Zdorove zhenschinyi 10(46):50–54.

16. Tatarchuk TF, Efimenko OA. 2012. Gormonalnyie i negormonalnyie aspektyi disgormonalnyih zabolevaniy molochnyih zhelez. Zdorove zhenschinyi 12(73):34–36.

17. Tatarchuk TF, Efimenko OA, Tutchenko TN. 2009. Mastodiniya na fone hronicheskogo stressa u zhenschin aktivnogo reproduktivnogo vozrasta. Zdorove zhenschinyi 10(46):50–54.

18. Tatarchuk TF, Kalugina LV, Efimenko OA. 2012. Opyit lecheniya mastalgii u patsientok s disgormonalnyimi zabolevaniyami molochnoy zhelezyi. Reproduktivnaya endokrinologiya 3(5):63–68.

19. Chistyakov SS, Grebennikova OP, Shikina VE. 2003. Kompleksnoe lechenie fibrozno-kistoznoy bolezni. RMZh. 11:666–670.

20. Tatarchuk TF, Efimenko OA, Vasilchenko LA, Yarotskaya NV. 2010. Enzimoterapiya v lechenii tsiklicheskoy mastodinii u zhenschin s disgormonalnyimi zabolevaniyami molochnyih zhelez. Zdorove zhenschinyi 5(51):58–61.

21. Geneviиve Plu-BureauMonique G Lк, Regine Sitruk-Ware, Jean-Christophe Thalabard. 2006. Cyclical mastalgia and breast cancer risk: results of a French cohort study. Cancer Epidemiol Biomarkers Prev. 15(6):1229–31. http://dx.doi.org/10.1158/1055-9965.EPI-05-0745; PMid:16775187

22. Khan SA, Apkarian AV. 2002. Mastalgia and breast cancer: a protective association? Cancer Detect Prev. 26(3):192–6. http://dx.doi.org/10.1016/S0361-090X(02)00065-X